Skip to main content




Principal Investigator


Boehringer Ingelheim Pharmaceuticals, Inc

This study is being done to: Test the safety and effectiveness of the study drug, BI 655130, in subjects with UC. Find the best dose of BI 655130 that can be used in future clinical studies without causing unacceptable side effects. Different doses of the study drug BI 655130 will be tested to see which dose has less unacceptable side effects and is more effective in subjects with UC. In this study you will either get the study drug BI 655130 or a placebo. Test how the study drug BI 655130 is used by the body, how fast or slow the study drug moves through or out of the body, and how the body reacts to the study drug.BI 655130 has not been approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease. The study drug is experimental for this study.

This study is currently enrolling.